1. Home
  2. EQBK vs MNKD Comparison

EQBK vs MNKD Comparison

Compare EQBK & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equity Bancshares Inc.

EQBK

Equity Bancshares Inc.

HOLD

Current Price

$49.79

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$3.97

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQBK
MNKD
Founded
2002
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2015
2004

Fundamental Metrics

Financial Performance
Metric
EQBK
MNKD
Price
$49.79
$3.97
Analyst Decision
Hold
Buy
Analyst Count
3
8
Target Price
$51.33
$8.69
AVG Volume (30 Days)
74.3K
4.2M
Earning Date
04-14-2026
05-06-2026
Dividend Yield
1.59%
N/A
EPS Growth
N/A
N/A
EPS
2.06
N/A
Revenue
N/A
$348,966,000.00
Revenue This Year
$74.58
$35.81
Revenue Next Year
$5.11
$11.89
P/E Ratio
$24.14
N/A
Revenue Growth
N/A
22.23
52 Week Low
$38.60
$2.23
52 Week High
$52.27
$6.51

Technical Indicators

Market Signals
Indicator
EQBK
MNKD
Relative Strength Index (RSI) 43.46 48.70
Support Level $44.45 $3.74
Resistance Level $50.07 $4.23
Average True Range (ATR) 0.83 0.17
MACD -0.24 -0.00
Stochastic Oscillator 31.77 45.30

Price Performance

Historical Comparison
EQBK
MNKD

About EQBK Equity Bancshares Inc.

Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: